We are delighted to share that 4Moving Biotech, a spin-off of 4P-Pharma, has enrolled the first patient in its Phase 2a clinical trial, INFLAM MOTION.
The study will evaluate 4P004, a first-in-class intra-articular GLP-1 therapy, in 129 patients with knee osteoarthritis (OA) across Europe and North America.
We extend our sincere thanks to all partners, investigators, and patients who made this milestone possible.
